{
    "nct_id": "NCT05256641",
    "official_title": "Acalabrutinib Maintenance Following Cellular Therapy for Large B-Cell Lymphoma Patients at Very High Risk for Relapse",
    "inclusion_criteria": "* Ages 18-70 years\n* One of the following:\n\n  * Patients undergoing autologous stem cell transplantation (ASCT) or any Food and Drug Administration (FDA)-approved chimeric antigen receptor (CAR) T-cell therapy product for:\n\n    * High grade B-cell lymphoma (double or triple hit) with rearrangements in bcl-2 and/or bcl-6, and rearrangement in myc\n    * Large B-cell lymphoma with a history of secondary CNS involvement\n    * Histologic transformation of indolent lymphoma to large B-cell lymphoma, including marginal zone lymphoma, follicular lymphoma, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), lymphoplasmacytic leukemia, or Waldenstrom macroglobulinemia\n    * High risk international prognostic index (IPI) score 4 or 5, at diagnosis or prior to CAR T-cell leukapheresis\n  * Patients undergoing allogeneic hematopoietic cell transplantation (alloHCT) for large B-cell lymphoma\n* Eastern Cooperative Oncology Group (ECOG) 0-2\n* Requirements for post-ASCT and post-alloHCT participants:\n\n  * Disease status of partial response (PR) or complete response (CR) prior to transplantation\n  * Receive reduced-intensity conditioning regimen\n  * Enrollment no later than day +90\n* Requirements for post-CAR T-cell therapy participants:\n\n  * Disease status of PR or CR after post-CAR T-cell therapy positron emission tomography (PET)-computed tomography (CT) at 1-3 months\n  * Enrollment no later than day +104\n* Ability to give full informed consent\n* Female subjects who are sexually active and can bear children must agree to use highly effective forms of contraception while on the study and for 2 days after the last dose of acalabrutinib\n* Willing and able to participate in all required evaluations and procedures in this study protocol, including swallowing capsules and tablets without difficulty\n* Absolute neutrophil count (ANC) > 500/uL (microliters)\n* Platelets > 50,000/uL independent of transfusions\n* Hemoglobin > 8 g/dL independent of transfusions\n* Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN)\n* Total bilirubin =< 1.5 x ULN, unless directly attributable to Gilbert's syndrome\n* Creatinine clearance >= 60 mL/min based on Cockcroft-Gault glomerular filtration rate (GFR) and serum creatinine (Cr) =< 1.8 mg/dL\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 70 Years",
    "exclusion_criteria": "* Cord blood as donor source in alloHCT\n* New York Heart Association Class III or IV\n* Left ventricular ejection fraction < 50%\n* Estimated glomerular filtration rate < 30 mL/min\n* Concurrent long-term use of posaconazole or other strong CYP3A4 inhibitors and unable to replace with equivalent medication\n* Acute or chronic graft-versus-host disease (GvHD) >= stage 3 at time of enrollment\n* Received packed red blood cells (pRBC) transfusion within the past 2 weeks\n* Received platelet transfusion within the past 1 week\n* Active invasive fungal infection\n* Active bacterial or viral infection until resolution of the infection\n* History of or ongoing confirmed progressive multifocal leukoencephalopathy (PML)\n* Received any investigational drug within 30 days or 5 half-lives (whichever is shorter) before first dose of study drug\n* Major surgical procedure within 30 days before the first dose of study drug. Note: If a subject had major surgery, they must have recovered adequately from any toxicity and/or complications from the intervention before the first dose of study drug\n* Refractory nausea and vomiting, inability to swallow the formulated product, or malabsorption syndrome; chronic gastrointestinal disease, gastric restrictions, or bariatric surgery such as gastric bypass; partial or complete bowel obstruction, or previous significant bowel resection that would preclude adequate absorption, distribution, metabolism, or excretion of study treatment\n* Received a live virus vaccination within 28 days of first dose of study drug\n* Known history of infection with human immunodeficiency virus (HIV)\n* History of bleeding diathesis (e.g., hemophilia, von Willebrand disease)\n* Requires or receiving anticoagulation with warfarin or equivalent vitamin K antagonists\n* Requires treatment with a strong cytochrome P450 3A (CYP3A) inhibitor or inducer. The use of strong CYP3A inhibitors within 1 week or strong CYP3A inducers within 3 weeks of the first dose of study drug is prohibited\n* Breastfeeding or pregnant\n* Concurrent participation in another therapeutic clinical trial",
    "miscellaneous_criteria": ""
}